Artiva Biotherapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $0 | $251,000 | $32.9M | — |
| Research and development | $69.5M | $50.3M | $50.3M | — |
| Operating expenses | $89.8M | $67.5M | $64.2M | — |
| Operating income | -$89.8M | -$67.3M | -$30.7M | — |
| Pretax income | — | -$65.4M | -$28.6M | — |
| Income tax expense | $0 | $0 | $72,000 | — |
| Net income | -$83.9M | -$65.4M | -$28.7M | — |
| Balance Sheet | ||||
| Cash and equivalents | $26.7M | $40.2M | $53.5M | — |
| Current assets | $112.7M | $188.6M | $79.8M | — |
| Total assets | $130.9M | $209.6M | $105.1M | — |
| Current liabilities | $13.1M | $12.3M | $12.2M | — |
| Total liabilities | $21.0M | $22.9M | $50.7M | — |
| Stockholders' equity | $110.0M | $186.6M | -$162.0M | -$140.7M |
| Cash Flow Statement | ||||
| Cash from operations | -$76.8M | -$55.0M | -$47.4M | — |
| Depreciation and amortization | $2.6M | $2.4M | $2.3M | — |
| Stock-based compensation | $6.8M | $7.0M | $7.1M | — |
| Capital expenditure | $2.6M | $642,000 | $3.3M | — |
| Free cash flow | -$79.3M | -$55.7M | -$50.7M | — |
| Impairments | $0 | $0 | $0 | — |
Shares outstanding 24.7M
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.